DEVELOPMENT OF TRANSIENT THYROID-DISEASE AND REACTION DURING TREATMENT OF CHRONIC HEPATITIS-C WITH INTERFERON

被引：24

作者：

KODAMA, T

KATABAMI, S

KAMIJO, K

KATANUMA, A

YAMASHITA, K

AZUMA, N

TAMAKI, T

YACHI, A

机构：

[1] Department of Internal Medicine, Muroran City General Hospital, Muroran, 051

[2] Department of Internal Medicine (Section 1), Sapporo Medical College, Sapporo

来源：

JOURNAL OF GASTROENTEROLOGY | 1994年 / 29卷 / 03期

关键词：

THYROID DISEASE; INTERFERON; CHRONIC HEPATITIS-C;

D O I：

10.1007/BF02358367

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Six of 50 (12%) patients with chronic hepatitis C who were treated with interferon developed thyroid disease or an autoimmune thyroid reaction while undergoing treatment. One patient developed silent thyroiditis, with an increase in serum tri-iodothyronine (T3), thyroxine (T4), free T3, free T4, and markedly suppressed thyroid-stimulating hormone (TSH) levels, accompanied by the appearance of both antithyroglobulin (TgAb) and antimicrosomal antibodies (McAb). One patient developed hypothyroidism in association with moderately elevated TSH levels and high titers of McAb. TSH, TgAb, and McAb levels returned to the initial values at least 4 months after the end of interferon treatment (9 months of follow up). Four patients whose TgAb and/or McAb levels were elevated during treatment with interferon had been diagnosed as having subclinical autoimmune thyroiditis; however, their thyroid function remained in the normal range. These results suggested that treatment with interferon can cause a transient autoimmune thyroid reaction and disease as a side effect.

引用

页码：289 / 292

页数：4

共 21 条

[1]

Choo Q-L, Kuo G., Weiner A.J., Et al., Isolation of cDNA clone derived from a blood bone non-A non-B viral hepatitis genome, Science, 244, pp. 359-362, (1989)

[2]

Kuo G., Choo Q-L, Alter H.J., Et al., An assay for circulating antibodies to a major etiologic virus of human non-A non-B hepatitis, Science, 244, pp. 362-364, (1989)

[3]

Okamoto H., Okada S., Sugiyama Y., Et al., The 5′-terminal sequence of hepatitis C virus genome, Jpn J Exp Med, 60, pp. 167-177, (1990)

[4]

Hoofnagle J., Di Bisceglie A.M., Treatment of chronic type C hepatitis with alpha interferon, Semin Liver Dis, 9, pp. 259-263, (1989)

[5]

Shindo M., Di Bisceglie A.M., Cheung L., Et al., Decrease in serum hepatitis C viral RNA during alpha interferon therapy for chronic hepatitis C, Ann Intern Med, 115, pp. 700-704, (1991)

[6]

Burman P.I.A., Totterman T.H., Oberg K., Et al., Thyroid autoimmunity in patients on long-term therapy with leukocytederived interferon, J Clin Endocrinol Metab, 63, pp. 1086-1090, (1986)

[7]

Giles F.J., Worman C.P., Jewell A.P., Et al., Recombinant alphainterferons, thyroid irradiation and thyroid disease, Acta Haematol, 85, pp. 160-163, (1991)

[8]

Nakamotomo A., Inagaki Y., Kitano Y., Et al., A case of chronic active hepatitis type C associated with hyperthyroidism following a long-term interferon therapy, Acta Hepatol Jpn, 32, pp. 863-867, (1991)

[9]

Maccari S., Bassi C., Giovannini A.G., Et al., A case of arthropathy and hypothyroidism during recombinant alpha-interferon therapy, Clin Rheumatol, 10, pp. 452-454, (1991)

[10]

Marcellin P., Pouteau M., Renard P., Et al., Sustained hypothyroidism induced by recombinant α interferon in patients with chronic hepatitis C, Gut, 33, pp. 855-856, (1992)

← 1 2 3 →